Literature DB >> 28549636

Amplitude-Integrated Electroencephalography Improves the Identification of Infants with Encephalopathy for Therapeutic Hypothermia and Predicts Neurodevelopmental Outcomes at 2 Years of Age.

Janne Helen Skranes1, Gro Løhaugen2, Eva Margrethe Schumacher3, Damjan Osredkar4, Andres Server5, Frances Mary Cowan6, Tom Stiris1, Drude Fugelseth1, Marianne Thoresen7.   

Abstract

OBJECTIVES: To examine whether using an amplitude-integrated electroencephalography (aEEG) severity pattern as an entry criterion for therapeutic hypothermia better selects infants with hypoxic-ischemic encephalopathy and to assess the time-to-normal trace for aEEG and magnetic resonance imaging (MRI) lesion load as 24-month outcome predictors. STUDY
DESIGN: Forty-seven infants meeting Norwegian therapeutic hypothermia guidelines were enrolled prospectively. Eight-channel EEG/aEEG was recorded from 6 hours until after rewarming, and read after discharge. Neonatal MRI brain scans were scored for summated (range 0-11) regional lesion load. A poor outcome at 2 years was defined as death or a Bayley Scales of Infant-Toddler Development cognitive or motor composite score of <85 or severe hearing or visual loss.
RESULTS: Three severity groups were defined from the initial aEEG; continuous normal voltage (CNV; n = 15), discontinuous normal voltage (DNV; n = 18), and a severe aEEG voltage pattern (SEVP; n = 14). Any seizure occurrence was 7% CNV, 50% DNV, and 100% SEVP. Infants with SEVP with poor vs good outcome had a significantly longer median (IQR) time-to-normal trace: 58 hours (9-79) vs 18 hours (12-19) and higher MRI lesion load: 10 (3-10) vs 2 (1-5). A poor outcome was noted in 3 of 15 infants with CNV, 4 of 18 infants with DNV, and 8 of 14 infants with SEVP. Using multiple stepwise linear regression analyses including only infants with abnormal aEEG (DNV and SEVP), MRI lesion load significantly predicted cognitive and motor scores. For the SEVP group alone, time-to-normal trace was a stronger outcome predictor than MRI score. No variable predicted outcome in infants with CNV.
CONCLUSIONS: Selection of infants with encephalopathy for therapeutic hypothermia after perinatal asphyxia may be improved by including only infants with an early moderate or severely depressed background aEEG trace.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI lesion load; MRI severity scoring; amplitude-integrated EEG; newborn; outcome prediction; patient selection; selection criteria; therapeutic hypothermia; time-to-normal trace

Mesh:

Year:  2017        PMID: 28549636     DOI: 10.1016/j.jpeds.2017.04.041

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Early spectral EEG in preterm infants correlates with neurocognitive outcomes in late childhood.

Authors:  Tone Nordvik; Eva M Schumacher; Pål G Larsson; Are H Pripp; Gro C Løhaugen; Tom Stiris
Journal:  Pediatr Res       Date:  2022-01-10       Impact factor: 3.953

2.  Neurodevelopmental Outcomes in Neonates with Mild Hypoxic Ischemic Encephalopathy Treated with Therapeutic Hypothermia.

Authors:  Rakesh Rao; Shamik Trivedi; Amy Distler; Steve Liao; Zachary Vesoulis; Christopher Smyser; Amit M Mathur
Journal:  Am J Perinatol       Date:  2019-01-04       Impact factor: 1.862

3.  Cytokine and chemokine responses to injury and treatment in a nonhuman primate model of hypoxic-ischemic encephalopathy treated with hypothermia and erythropoietin.

Authors:  Thomas R Wood; Phuong T Vu; Bryan A Comstock; Janessa B Law; Dennis E Mayock; Patrick J Heagerty; Thomas Burbacher; Theo K Bammler; Sandra E Juul
Journal:  J Cereb Blood Flow Metab       Date:  2021-02-07       Impact factor: 6.200

4.  Early Determination of Prognosis in Neonatal Moderate or Severe Hypoxic-Ischemic Encephalopathy.

Authors:  Namasivayam Ambalavanan; Seetha Shankaran; Abbot R Laptook; Benjamin A Carper; Abhik Das; Waldemar A Carlo; C Michael Cotten; Andrea F Duncan; Rosemary D Higgins
Journal:  Pediatrics       Date:  2021-05-13       Impact factor: 9.703

5.  Seizure Characteristics and Background Amplitude-Integrated Electroencephalography Activity in Neonatal Rats Subjected to Hypoxia-Ischemia.

Authors:  Xiaowei Sun; Fenqin Xue; Jialin Wen; Limin Gao; Yang Li; Qianqian Jiang; Lijun Yang; Hong Cui
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

6.  Prognostic Value of Clinical Tests in Neonates With Hypoxic-Ischemic Encephalopathy Treated With Therapeutic Hypothermia: A Systematic Review and Meta-Analysis.

Authors:  Weiqin Liu; Qifen Yang; Hong Wei; Wenhui Dong; Ying Fan; Ziyu Hua
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

7.  Seizures severity during rewarming can predict seizure outcomes of infants with neonatal hypoxic-ischemic encephalopathy following therapeutic hypothermia.

Authors:  Yun-Ju Chen; Ming-Chou Chiang; Jainn-Jim Lin; I-Jun Chou; Yi-Shan Wang; Shu-Sing Kong; I-Chen Su; Elaine Chen; Tze Yee Diane Mok; Reyin Lien; Kuang-Lin Lin
Journal:  Biomed J       Date:  2020-06-30       Impact factor: 4.910

8.  Perspectives from the Society for Pediatric Research. Neonatal encephalopathy clinical trials: developing the future.

Authors:  Kristen L Benninger; Terrie E Inder; Amy M Goodman; C Michael Cotten; Douglas R Nordli; Tushar A Shah; James C Slaughter; Nathalie L Maitre
Journal:  Pediatr Res       Date:  2020-03-27       Impact factor: 3.756

9.  Morphine and fentanyl exposure during therapeutic hypothermia does not impair neurodevelopment.

Authors:  Julia K Gundersen; Ela Chakkarapani; Sally Jary; David A Menassa; Emma Scull-Brown; Adam Frymoyer; Lars Walløe; Marianne Thoresen
Journal:  EClinicalMedicine       Date:  2021-06-05

10.  MRI combined with early clinical variables are excellent outcome predictors for newborn infants undergoing therapeutic hypothermia after perinatal asphyxia.

Authors:  Marianne Thoresen; Sally Jary; Lars Walløe; Mathias Karlsson; Miriam Martinez-Biarge; Ela Chakkarapani; Frances M Cowan
Journal:  EClinicalMedicine       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.